Washed microbiota transplantation for ribotype 027 Clostridioides difficile infection in a pregnant woman with a two-year follow-up: A case report

Abstract

Clostridioides difficile (C. difficile) is one of the major causes of nosocomial infections. Pregnant women, who are generally considered at low risk for C. difficile infection (CDI), have attracted attention because of an increasing number of reports. Oral vancomycin, the only first-line treatment for pregnant women infected with C. difficile, has been associated with increasing strain resistance, leading to decreased efficacy. Fecal microbiota transplantation (FMT) is recommended for severe, fulminant, and recurrent CDI; however, it is generally avoided in pregnant women because of safety concerns. We report a case of a pregnant woman with a primary ribotype 027 CDI who experienced a successful outcome with washed microbiota transplantation (WMT), an improved form of FMT, via enema. The specific strain of ribotype 027 is related to severe outcomes but has not previously been reported in pregnant women. The follow-up lasted for two years, during which the patient's diarrhea was fully alleviated without recurrence. The baby showed normal growth and development, and no adverse events were recorded for either. This case provides evidence for the efficacy and safety of WMT in pregnant women infected with C. difficile, indicating that WMT via enema may be a viable therapeutic strategy for this population for treating CDI.

Keywords

fecal microbiota transplant / pregnant women / Clostridioides difficile

References

[1] Eubank TA, Dureja C, Garey KW, et al. Reduced vancomycin susceptibility in Clostridioides difficile is associated with lower rates of initial cure and sustained clinical response[J]. Clin Infect Dis, 2024, 79(1): 15-21. doi: 10.1093/cid/ciae087

[2] Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: Prevention, diagnosis, and treatment of Clostridioides difficile infections[J]. Am J Gastroenterol, 2021, 116(6): 1124-1147. doi: 10.14309/ajg.0000000000001278

[3] Rao K, Micic D, Natarajan M, et al. Clostridium difficile ribotype 027: Relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality[J]. Clin Infect Dis, 2015, 61(2): 233-241. doi: 10.1093/cid/civ254

[4] Ianiro G, Maida M, Burisch J, et al. Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: A systematic review and meta-analysis[J]. United European Gastroenterol J, 2018, 6(8): 1232-1244. doi: 10.1177/2050640618780762

[5] Zhang T, Lu G, Zhao Z, et al. Washed microbiota transplantation vs. manual fecal microbiota transplantation: Clinical findings, animal studies and in vitro screening[J]. Protein Cell, 2020, 11(4): 251-266. doi: 10.1007/s13238-019-00684-8

[6] Fecal Microbiota Transplantation-Standardization Study Group. Nanjing consensus on methodology of washed microbiota transplantation[J]. Chin Med J (Engl), 2020, 133(19): 2330-2332. doi: 10.1097/CM9.0000000000000954

[7] Wu X, Ai RJ, Xu J, et al. Washed microbiota transplantation for Clostridioides difficile infection: A national multicenter real-world study[J]. J Digest Dis, 2023, 24(10): 540-549. doi: 10.1111/1751-2980.13227

[8] Mattila E, Uusitalo-Seppälä R, Wuorela M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection[J]. Gastroenterology, 2012, 142(3): 490-496. doi: 10.1053/j.gastro.2011.11.037

[9] Marcella C, Cui B, Kelly CR, et al. Systematic review: The global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020[J]. Aliment Pharmacol Ther, 2021, 53(1): 33-42. doi: 10.1111/apt.16148

[10] Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: The efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection[J]. Aliment Pharmacol Ther, 2017, 46(5): 479-493. doi: 10.1111/apt.14201